Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GSK
Biotech
GSK pays $1.2B upfront for Boston's lead liver disease drug
GSK is brushing off dropping a cancer asset on Tuesday by snagging a late-stage liver disease drug for a hefty $1.2 billion upfront.
Ben Adams
May 14, 2025 2:53am
GSK axes $625M TIGIT drug as midphase data disappoint
May 13, 2025 9:44am
GSK posts phase 3 itch data as it closes in on FDA approval
May 8, 2025 8:50am
GSK pens $2.5B pact for ABL's blood-brain barrier-bypassing tech
Apr 7, 2025 7:00am
LifeMine lays off staff to focus on lead immunology asset
Mar 31, 2025 5:26pm
Sanofi snatches GSK R&D leader
Mar 31, 2025 1:26pm
